GlassScriptPhysician profile
Jacqueline Cain
NPI 1891708533
$2,334.97
in general payments reported to CMS, 2019-2025
22 companies · $243 in 2025
The $243 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $131 · 2020: $121 · 2021: $333 · 2022: $905 · 2023: $392 · 2024: $209 · 2025: $243.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $845.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $844.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $460.15 | 2022-2025 | |
| Astellas Pharma US INC | $333.93 | 2020-2023 | Myrbetriq, Veozah |
| Abbott Laboratories | $269.60 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Abbvie INC. | $253.24 | 2022-2025 | Vraylar |
| Janssen Pharmaceuticals, INC | $184.10 | 2019-2023 | Spravato |
| Novo Nordisk INC | $127.60 | 2021-2025 | Rybelsus, Ozempic |
| Daiichi Sankyo INC. | $95.07 | 2022 | |
| Lilly USA, LLC | $92.01 | 2021-2024 | Mounjaro |
| Glaxosmithkline, LLC. | $75.07 | 2020-2024 | Trelegy Ellipta, Arexvy |
| Sunovion Pharmaceuticals INC. | $74.97 | 2022 | |
| Amgen INC. | $73.51 | 2020-2025 | Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $57.07 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.61 | 2020-2022 | |
| Eisai INC. | $41.57 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $34.16 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $20.77 | 2023 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $18.07 | 2022 | |
| Antares Pharma, INC. | $15.49 | 2020 | |
| Paratek Pharmaceuticals, INC. | $14.86 | 2022 | |
| Merck Sharp & Dohme LLC | $14.42 | 2024 | Capvaxive, Gardasil, Vaxelis |
| Novartis Pharmaceuticals Corporation | $14.26 | 2021 | |
| Phathom Pharmaceuticals, INC. | $13.44 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacqueline Cain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.